Benjamin argues that patients didn't become pickier; loosened rules on cross-state licensing, prescribing, and pharmacy shipping made convenience possible. Convenience alone makes a company one more online prescriber, so the real value is the specialized care it enables.
Benjamin sees the Lilly and Hims GLP-1 deal as a sign that large manufacturers will partner with online prescribers. If new hair compounds arrive as add-ons, Benjamin argues, specialist dermatologists are better suited than volume platforms to design each patient's combination.
Benjamin sees CVS splitting off its pharmacy arm as healthy, since one company acting as clinic, pharmacy, and business blurs who each decision serves. Benjamin points to Happy Head, where dermatologists alone prescribe, as a model to copy and publish.